日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Corrigendum to "P53-independent partial restoration of the p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9" [Neoplasia, volume 23 (2021) 304325]

对“通过 ERK1/2 和 CDK9 对 ATF4 转录的调控,在 p53 突变的肿瘤中实现 p53 通路的 P53 非依赖性部分恢复”的更正 [Neoplasia,第 23 卷(2021 年)304325]

Tian, Xiaobing; Ahsan, Nagib; Lulla, Amriti; Lev, Avital; Abbosh, Philip; Dicker, David T; Zhang, Shengliang; El-Deiry, Wafik S

Low-Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer.

低分子量细胞周期蛋白 E 使三阴性乳腺癌对 PKMYT1 抑制剂敏感

Li Mi, Lulla Amriti R, Wang Yan, Tsavaschidis Spyros, Wang Fuchenchu, Karakas Cansu, Nguyen Tuyen D T, Bui Tuyen N, Pina Marc A, Chen Mei-Kuang, Mastoraki Sofia, Multani Asha S, Fowlkes Natalie W, Sahin Aysegul, Marshall C Gary, Hunt Kelly K, Keyomarsi Khandan

LMW cyclin E and its novel catalytic partner CDK5 are therapeutic targets and prognostic biomarkers in salivary gland cancers

低分子量细胞周期蛋白E及其新型催化伴侣CDK5是唾液腺癌的治疗靶点和预后生物标志物。

Lulla, Amriti R; Akli, Said; Karakas, Cansu; Ha, Min Jin; Fowlkes, Natalie W; Mitani, Yoshitsugu; Bui, Tuyen; Wang, Jing; Rao, Xiayu; Hunt, Kelly K; Meijer, Laurent; El-Naggar, Adel K; Keyomarsi, Khandan

Correction: Discovery and clinical introduction of first-in-class imipridone ONC201

更正:首创药物咪吡啶酮 ONC201 的发现和临床应用

Allen, Joshua E; Kline, C Leah B; Prabhu, Varun V; Wagner, Jessica; Ishizawa, Jo; Madhukar, Neel; Lev, Avital; Baumeister, Marie; Zhou, Lanlan; Lulla, Amriti; Stogniew, Martin; Schalop, Lee; Benes, Cyril; Kaufman, Howard L; Pottorf, Richard S; Nallaganchu, B Rao; Olson, Gary L; Al-Mulla, Fahd; Duvic, Madeleine; Wu, Gen Sheng; Dicker, David T; Talekar, Mala K; Lim, Bora; Elemento, Olivier; Oster, Wolfgang; Bertino, Joseph; Flaherty, Keith; Wang, Michael L; Borthakur, Gautam; Andreeff, Michael; Stein, Mark; El-Deiry, Wafik S

Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies

首创小分子药物伊米普利酮 ONC201 在血液系统恶性肿瘤中的单药及协同联合疗效

Prabhu, Varun V; Talekar, Mala K; Lulla, Amriti R; Kline, C Leah B; Zhou, Lanlan; Hall, Junior; Van den Heuvel, A Pieter J; Dicker, David T; Babar, Jawad; Grupp, Stephan A; Garnett, Mathew J; McDermott, Ultan; Benes, Cyril H; Pu, Jeffrey J; Claxton, David F; Khan, Nadia; Oster, Wolfgang; Allen, Joshua E; El-Deiry, Wafik S

Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212.

对伊米普利酮家族(临床阶段抗癌小分子 ONC201 的类似物)的临床前评估显示,ONC212 具有强大的抗癌作用

Wagner Jessica, Kline Christina Leah, Ralff Marie D, Lev Avital, Lulla Amriti, Zhou Lanlan, Olson Gary L, Nallaganchu Bhaskara Rao, Benes Cyril H, Allen Joshua E, Prabhu Varun V, Stogniew Martin, Oster Wolfgang, El-Deiry Wafik S

Current treatment of early breast cancer: adjuvant and neoadjuvant therapy

早期乳腺癌的当前治疗方法:辅助治疗和新辅助治疗

Miller, Elizabeth; Lee, Hee Jin; Lulla, Amriti; Hernandez, Liz; Gokare, Prashanth; Lim, Bora